1.
Czapska M, Babkiewicz K, Pabis S, Skórzyńska-Dziduszko K. Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus. J Educ Health Sport [Internet]. 2018 Dec. 14 [cited 2024 Apr. 19];8(12):335-51. Available from: https://apcz.umk.pl/JEHS/article/view/6378